g(HbF): a genetic model of fetal hemoglobin in sickle cel

Blood Advances

2, 235-239

DOI: 10.1182/bloodadvances.2017009811

Citation Report

#	Article	IF	Citations
1	Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study. American Journal of Hematology, 2018, 93, 1411-1419.	2.0	17
2	Sickle cell disease in the era of precision medicine: looking to the future. Expert Review of Precision Medicine and Drug Development, 2019, 4, 357-367.	0.4	7
3	The association of HBG2 , BCL11A, and HMIP polymorphisms with fetal hemoglobin and clinical phenotype in Iraqi Kurds with sickle cell disease. International Journal of Laboratory Hematology, 2019, 41, 87-93.	0.7	6
4	Genetic Modifiers of Fetal Haemoglobin in Sickle Cell Disease. Molecular Diagnosis and Therapy, 2019, 23, 235-244.	1.6	32
5	Emerging Genetic Therapy for Sickle Cell Disease. Annual Review of Medicine, 2019, 70, 257-271.	5.0	90
6	A gain of function variant in PIEZO1 (E756del) and sickle cell disease. Haematologica, 2019, 104, e91-e93.	1.7	20
7	F cell numbers are associated with an Xâ€linked genetic polymorphism and correlate with haematological parameters in patients with sickle cell disease. British Journal of Haematology, 2020, 191, 888-896.	1.2	10
8	Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes. Journal of Clinical Medicine, 2020, 9, 3782.	1.0	27
9	Association of HMIP1 C-893A polymorphism and disease severity in patients with sickle cell anemia. Hematology, Transfusion and Cell Therapy, 2020, 43, 243-248.	0.1	2
10	Fetal hemoglobin in sickle cell anemia. Blood, 2020, 136, 2392-2400.	0.6	43
11	Control of fetal globin expression in man: new opportunities to challenge past discoveries. Experimental Hematology, 2020, 92, 43-50.	0.2	5
12	XmnI Polymorphism in Sickle Cell Disease in North Morocco. Hemoglobin, 2020, 44, 190-194.	0.4	2
13	Sickle cell disease in Sri Lanka: clinical and molecular basis and the unanswered questions about disease severity. Orphanet Journal of Rare Diseases, 2020, 15, 177.	1.2	6
14	Multi-Locus Models to Address Hb F Variability in Portuguese Î²-Thalassemia Carriers. Hemoglobin, 2020, 44, 113-117.	0.4	2
15	HbF-promoting polymorphisms may specifically reduce the residual risk of cerebral vasculopathy in SCA children with alpha-thalassemia. Clinical Hemorheology and Microcirculation, 2021, 77, 267-272.	0.9	2
16	Non-S Sickling Hemoglobin Variants: Historical, Genetic, Diagnostic, and Clinical Perspectives. Oman Medical Journal, 2021, 36, e261-e261.	0.3	2
17	A Machine Learning Model for Predicting Fetal Hemoglobin Levels in Sickle Cell Disease Patients. Lecture Notes in Networks and Systems, 2022, , 79-91.	0.5	0
18	Sickle cell disease and fetal hemoglobin. Saudi Journal of Medicine and Medical Sciences, 2018, 6, 131.	0.3	0

#	Article	IF	Citations
19	Perspective: A novel prognostic for sickle cell disease. Saudi Journal of Medicine and Medical Sciences, 2018, 6, 133.	0.3	2
20	Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea. Haematologica, 2022, 107, 1577-1588.	1.7	6
21	Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). Haematologica, 2021, 106, 1770-1773.	1.7	10
22	Phenotypic variation in sickle cell disease: the role of beta globin haplotype, alpha thalassemia, and fetal hemoglobin in HbSS. Expert Review of Hematology, 2022, 15, 107-116.	1.0	2
23	The COPILOT Raw Illumina Genotyping QC Protocol. Current Protocols, 2022, 2, e373.	1.3	5
24	Single Nucleotide Polymorphisms in XMN1-HBG2, HBS1L-MYB, and BCL11A and Their Relation to High Fetal Hemoglobin Levels That Alleviate Anemia. Diagnostics, 2022, 12, 1374.	1.3	2
25	Determinants of severity in sickle cell disease. Blood Reviews, 2022, 56, 100983.	2.8	13
26	Single nucleotide polymorphisms in SAR1A coding regions in sickle cell disease and their potential miRNA binding sites. EJHaem, 0, , .	0.4	1
27	Fetal hemoglobin-boosting haplotypes of BCL11A gene and HBS1L-MYB intergenic region in the prediction of clinical and hematological outcomes in a cohort of children with sickle cell anemia. Journal of Human Genetics, 0, , .	1.1	3
28	Variation and impact of polygenic hematologic traits in monogenic sickle cell disease. Haematologica, 2023, 108, 870-881.	1.7	4
29	A Versatile and Efficient Novel Approach for Mendelian Randomization Analysis with Application to Assess the Causal Effect of Fetal Hemoglobin on Anemia in Sickle Cell Anemia. Mathematics, 2022, 10, 3743.	1.1	0
30	Genetic Modifiers of Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2022, 36, 1097-1124.	0.9	4